Dark
Streaming/Mobile
Old Site
Home
Products
Help
Contact Us
Your Account
System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:39:53 EDT Wed 17 Apr 2024
Quotes
Streaming/Mobile
Quick Quotes (x20)
Symbol Search
Company Search
Market Depth
US Options
Montreal Options
Foreign Exchange
Download Close Prices
Short History
Quotes Help
Charts
12 Month Chart
Advanced Chart
Live Intraday Chart
Live Historical Chart
Live Java Intraday Chart
Live Java Historical Chart
Charts Help
News
News Search
SEDAR Search
SEDAR Alerts
News Help
Indexes
Major Indexes
US incl Dow Jones
NASDAQ
S&P CME
PBOT - Phil Ex
TSX - Toronto
TSX-V - TSX Venture
Indexes Help
Portfolio
View Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Value Portfolio
All Portfolios
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Edit Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Chart Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
Live Portfolio
Portfolio 1
Portfolio 2
Portfolio 3
Portfolio 4
Portfolio 5
Portfolio 6
Portfolio 7
Portfolio 8
Portfolio 9
Portfolio 10
View Portfolio News
Daily Summary
Portfolio Help
Analytics
Exchange Statistics
Most Active
Live Most Active
Block Trades
Broker Trades
Halted Stocks
Dividends
Participants
Companies
Trade Workstation
Company Picker
Short Positions
Broker Codes
Analytics Help
Mutual Funds
Mutual Fund Search
Targeted Holder Search
SEDAR Fund Search
Mutual Fund Help
Enter Symbol
or Name
USA
CA
Quote
Chart
News
Closes
Depth
Forgot password?
Trouble logging in?
Login to Stockwatch
Q:CHRS
- COHERUS BIOSCIENCES INC -
http://www.coherus.com
22:39:53 EDT
Sym-X
Bid - Ask
Last
Chg
%Ch
Vol
$Vol
#Tr
Open-Hi-Lo
Year Hi-Lo
Last Tr
News
Delay
CHRS
- Q
1.0
2.12
·
2.22
4.8
2.15
1,257.4
2,537
4,081
2.17
2.22
2.12
8.34 1.4301
18:11:36
Apr 08
15 min
RT 2¢
Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
Nasdaq Indicators -- Market:
Nasdaq
-- Bid Tick:
Down
-- UPC Restricted:
No
Fundamentals
·
Holders
·
Trade Workstation
·
Market Depth
·
3 Month Closes
·
Technical Charts
1 yr
|
2 yr
|
3 yr
|
5 yr
|
10 yr
|
15 yr
|
20 yr
·
Live Charts
1 yr
|
1 day
·
1yr Bulletins
·
Historical
·
Options
·
Portfolio
Recent Trades - Last 10 of 4081
More trades...
Time ET
Ex
Price
Change
Volume
18:11:36
Q
2.1899
0.0399
50
18:11:11
Q
2.1886
0.0386
50
16:38:59
Q
2.16
0.01
1,001
16:20:00
Q
2.15
254
16:17:14
Q
2.17
0.02
10
16:17:14
Q
2.17
0.02
190
16:16:22
Q
2.17
0.02
1
16:03:20
Q
2.20
0.05
671
16:02:36
Q
2.20
0.05
1,000
16:02:13
Q
2.20
0.05
1,001
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
Recent Bulletins
News Releases
In The News
Other
Date ET
Symbol
Type
Headline
2024-04-08 08:30
U:CHRS
News Release
200
Coherus Presents Preclinical Data for CHS-1000, a Novel Anti-ILT4 Antibody, at the 2024 AACR Annual Meeting
2024-03-13 16:01
U:CHRS
News Release
200
Coherus BioSciences Reports Fourth Quarter, Full Year 2023 Financial Results and Provides Current Business Update
2024-03-05 16:01
U:CHRS
News Release
200
Coherus to Report Fourth Quarter and Full Year 2023 Financial Results on March 13, 2024
2024-03-04 01:00
U:CHRS
News Release
200
Coherus Completes Divestiture of Ophthalmology Franchise
2024-02-23 17:33
U:CHRS
News Release
200
Coherus BioSciences Announces New Employment Inducement Grants
2024-02-21 08:30
U:CHRS
News Release
200
Coherus Announces U.S. Launch of UDENYCA ONBODY ¢ „ ¢ a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2024-02-05 08:00
U:CHRS
News Release
200
Coherus Amends Term Loan Agreement with Pharmakon Advisors, LP
2024-01-22 01:15
U:CHRS
News Release
200
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
2024-01-18 16:05
U:CHRS
News Release
200
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
2024-01-04 08:00
U:CHRS
News Release
200
INOVIO and Coherus Announce Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI ¢ „ ¢ (toripalimab-tpzi)
2024-01-03 09:00
U:CHRS
News Release
200
Coherus BioSciences Management to Present at the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 08:29
U:CHRS
News Release
200
Coherus Announces U.S. Launch of LOQTORZI ¢ „ ¢
2023-12-26 16:01
U:CHRS
News Release
200
Coherus Announces FDA Approval of UDENYCA ONBODY ¢ „ ¢, a Novel and Proprietary State-of-the-Art Delivery System for pegfilgrastim-cbqv
2023-12-22 17:00
U:CHRS
News Release
200
Coherus BioSciences Announces New Employment Inducement Grants
2023-12-11 08:30
U:CHRS
News Release
200
Coherus Announces Updated NCCN Clinical Practice Guidelines Positioning LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Preferred Category 1 Regimen for First-Line Treatment of Cancer of the Nasopharynx
2023-12-07 17:56
U:CHRS
News Release
200
Coherus BioSciences Announces CFO Transition Plans
2023-12-06 04:00
U:CHRS
News Release
200
Coherus Presents Phase 1/2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2023 ESMO Immuno-Oncology Congress
2023-11-28 11:16
U:CHRS
News Release
200
Coherus and Junshi Biosciences Announce Publication of Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Trial Evaluating LOQTORZI ¢ „ ¢ (toripalimab-tpzi) as Treatment for Nasopharyngeal Carcinoma, in the Journal of the American Medical As
2023-11-06 16:08
U:CHRS
News Release
200
Coherus BioSciences Reports Third Quarter 2023 Financial Results and Business Highlights
2023-11-03 08:30
U:CHRS
News Release
200
Coherus Presents Data from Next-generation Immuno-oncology Programs at 38th Annual Meeting of Society for Immunotherapy of Cancer (SITC)